498 results on '"Valentino, Leonard A."'
Search Results
52. Creating experimental bleeding variability in the mouse model of hemophilia A
53. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations
54. Diagnosis of Von Willebrand Disease in Children
55. Effects of neuroblastoma tumor gangliosides on platelet adhesion to collagen
56. β-Glucuronidase P408S, P415L mutations: evidence that both mutations combine to produce an MPS VII allele in certain Mexican patients
57. Arteriovenous fistula for long-term venous access for boys with hemophilia
58. Blood Safety and the Choice of Anti-Hemophilic Factor Concentrate
59. Future Aspects of Hemophilia Research and Care
60. Managing the Pediatric Patient and the Adolescent/Adult Transition
61. Current and Future Hemophilia Treatment Options Based on the 15th Annual Hemophilia Research Study Update
62. Randomized, controlled, multi-year study to evaluate joint outcomes in young children using recombinant factor VIII (Kogenate® FS): 05 PO 105
63. Gangliosides promote platelet adhesion and facilitate neuroblastoma cell adhesion under dynamic conditions simulating blood flow
64. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene
65. New anticoagulants in pediatrics
66. Central venous access devices in patients with hemophilia
67. A pregnant patient with renal vein thrombosis successfully treated with low-dose thrombolytic therapy: A case report
68. Women and girls’ participation in haemophilia clinical trials.
69. A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
70. Emicizumab: Review of the literature and critical appraisal
71. Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report
72. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide
73. Effects of neuroblastoma tumor gangliosides on platelet adhesion to collagen
74. Pushing the frontiers of medicine: innovations in haemophilia care.
75. Issues complicating precision dosing for factor VIII prophylaxis
76. Joint lavage followed by intra-articular injection of hyaluronic acid and/or corticosteroids in patients with severe hemophilic arthropathy of the knee: Is this intervention really effective?
77. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
78. The role of ultralarge multimers in recombinant human von Willebrand factor – a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease
79. The Safety of Hemophilia Product Use: a Simulation Analysis
80. Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis
81. Assessing Protection from Intracranial Hemorrhage in Clinical Studies for Investigational Agents in Patients with Hemophilia
82. Increased Risk of Adverse Bone Health Outcomes in People with Bleeding Disorders
83. Synergistic Effects of a Procoagulant Bispecific Antibody and Rescue Therapies on Thrombin Generation- a Potential Safety Risk
84. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.
85. Emicizumab: Review of the literature and critical appraisal.
86. Walking the Walk: Inclusion of Lived Experience Experts in the Design of the National Hemophilia Foundation's National Research Blueprint for Those Living with Inherited Bleeding Disorders
87. Hemophilia in the virtual clinic: Using telemedicine to manage chronic disease
88. An innovative outcome-based care and procurement model of hemophilia management
89. Orthopedic disorders of the knee in hemophilia: A current concept review
90. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy : results from the von Willebrand Disease Prophylaxis Network
91. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network
92. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy
93. Pushing the frontiers of medicine: innovations in haemophilia care
94. Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis
95. Rituximab for treatment of inhibitors in haemophilia A
96. Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein
97. Vitamin D Deficiency and Osteoporosis In Hemophilia: An Underappreciated Risk
98. Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc)
99. Biologic Response and Adverse Events To Stimate In Patients With Von Willebrand Disease
100. Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.